pEGFP-N1 hMOG-alpha1-EGFP Citations (2)

Originally described in: Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, Lutterotti A, Jarius S, Di Pauli F, Kuenz B, Ehling R, Hegen H, Deisenhammer F, Aboul-Enein F, Storch MK, Koson P, Drulovic J, Kristoferitsch W, Berger T, Reindl M J Neuroinflammation. 2011 Dec 28;8:184. doi: 10.1186/1742-2094-8-184. PubMed Journal

---

Articles Citing pEGFP-N1 hMOG-alpha1-EGFP

Articles
Loss of TMEM106B leads to myelination deficits: implications for frontotemporal dementia treatment strategies. Zhou X, Nicholson AM, Ren Y, Brooks M, Jiang P, Zuberi A, Phuoc HN, Perkerson RB, Matchett B, Parsons TM, Finch NA, Lin W, Qiao W, Castanedes-Casey M, Phillips V, Librero AL, Asmann Y, Bu G, Murray ME, Lutz C, Dickson DW, Rademakers R. Brain. 2020 Jun 1;143(6):1905-1919. doi: 10.1093/brain/awaa141. PubMed
Prevalence of anti-myelin oligodendrocyte glycoprotein antibodies across neuroinflammatory and neurodegenerative diseases. Trivedi RR, Archambault AS, Pavlak C, Gastaldi M, Cantoni C, Ghezzi L, Cross AH, Miller TM, Wu GF. J Neurol Sci. 2024 Jun 15;461:123041. doi: 10.1016/j.jns.2024.123041. Epub 2024 May 9. PubMed

If you have published an article using this material, please email us at to have your article added to this page.